A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults
← catalyst calendarNCT07768345 · readout in 531 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Prevention
Enrollment
440estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-31 | estimated | When the study began enrolling |
| Primary completion | 2028-02-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-02 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Respiratory Syncytial Virus (RSV)
Intervention
- Biological: RSVpreF Vaccine
Primary outcomes
what the primary-completion date above is the date OFPercentage of participants reporting local reactions
measured For up to 7 days after vaccination
Percentage of participants reporting systemic events
measured For up to 7 days after vaccination
Percentage of participants reporting adverse events
measured Through 1 month after vaccination
Percentage of participants reporting newly diagnosed chronic medical conditions
measured Through 12 months after vaccination
Percentage of participants reporting serious adverse events
measured Through 12 months after vaccination
Neutralizing Titers (NTs) for RSV A and RSV B expressed as Geometric Mean Titer (GMT)
measured Before vaccination, 1 month, 6 months and 12 months after vaccination
NTs for RSV A and RSV B expressed as Geometric Mean Fold Rise (GMFR)
measured Before vaccination, 1 month, 6 months and 12 months after vaccination
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed